Advanced Search

 

Study ID Status Title Patient Level Data
NUCA2010 Completed Lamivudine Compassionate Use for Patients with Decompensated Liver Injury Secondary to Hepatitis B Infection
NUCA3001 Completed A Randomized, Double-Blind, Multi-center Trial to Compare the Safety and Efficacy of 3TCTM Monotherapy Versus Zidovudine (ZDV) Monotherapy Versus 3TCTM Administered Concurrently with ZDV in the Treatment of HIV-1 Infected Patients who are ZDV-Naïve (?4 weeks) with CD4 Cell Counts of 200-500 cell ...
NUCA3002 Completed A Randomized 3TCTM, ddC Double-Blind (ZDV Open-labeled) Multi-center Trial to Evaluate the Safety and Efficacy of 3TCTM (low dose) Administered Concurrently with Zidovudine (ZDV) versus 3TCTM (high dose) Administered Concurrently with ZDV Versus Dideoxycytidine (ddC) Administered…
NUCA3005 Completed Lamivudine Open-label Protocol for Treatment of Patients with Hepatitis B Viral Infection After Liver Transplantation
NUCA3010 Completed A Study of Lamiviudine or Placebo in Patients with Chronic Hepatitis B Infection Who are Treatment Naive
NUCA3016 Completed A Five Year Final Study Report for NUCA/B3016 - A Long-Term Epidemiologic Study of Subjects Who Have Evidence of Possible Durable Response to Lamivudine in Phase II or Phase III Trials of Lamivudine
NUCA3021 Completed Lamivudine Compassionate Use Treatment Program for Subjects with Three Life-Threatening Forms of Hepatitis B Infection
NUCAB3011 Completed A Placebo Controlled Study of Lamivudine and Intron A in Patients with Chronic Hepatitis B Infection Who are Interferon a Non-Responders
NUCB1002 Completed A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) in Patients With Impaired Hepatic Function (Protocol No: C93-015)
NUCB1003 Completed A Study to Investigate the Pharmacokinetics of Lamivudine (GR109714X) Following Oral Dosing in Subjects With Impaired Renal Function
NUCB1004 Completed A study to investigate the comparative bioavailability of two oral formulations of GR109714X (Lamivudine).
NUCB1007 Completed A Study to Investigate the Pharmacokinetic Interaction Between Lamivudine and Alpha-Interferon in Healthy Subjects
NUCB1009 Completed A study to investigate the pharmacokinetics of lamivudine (GR109714X) in healthy male and female Chinese subjects.
NUCB2001 Completed A phase I/II study of the safety, pharmacokinetics and preliminary activity of 3TC (GR109714X) in HIV-positive, asymptomatic and mild ARC patients.
NUCB2002 Completed A Randomized, Multicentre, Single-blind (Patient), Placebo-controlled, Phase II, Dose-ranging Study to Determine the Pharmacokinetics, Safety and Preliminary Activity of Once Daily Lamivudine in Patients with Chronic Hepatitis B Infection
NUCB2003 Completed A Randomized, Multicentre, Single Blind (Patient) Study to Compare the Efficacy and Safety of 25 mg, 100 mg, and 300 mg Lamivudine, Once daily in patients with Chronic Hepatitis B Infection
NUCB2004 Completed A Randomized, Phase II, Single-blind (Patient), Placebo-controlled, Dose-ranging Study to Determine the Safety and Preliminary Activity of Lamivudine in Oriental Patients with Chronic Hepatitis B Infection
NUCB2005 Completed A Randomised, Phase II, Single-blind (Patient) Placebo-controlled, Dose-ranging Study to Determine the Safety and Preliminary Activity of Lamivudine in Oriental Patients with Chronic Hepatitis B Infection
NUCB2007 Completed A Double-blind, Placebo-controlled, Randomised, Parallel Group, Multicentre Study to Assess the Effect of Lamivudine on the Safety, Tolerability and Pharmacokinetics of Alpha-interferon in Patients Receiving Interferon for Chronic Hepatitis B Infection
NUCB2008 Completed An Open, Multicentre Study to Determine the Safety, Pharmacokinetics and Preliminary Efficacy of Lamivudine in Chronic Hepatitis B Patients in End Stage Liver Failure Undergoing Liver Transplantation
NUCB2010 Completed An Open Phase II Pilot Study to Determine the Safety and Activity of Lamivudine in Patients with Chronic Hepatitis C Infection
NUCB2013 Completed An Open, Randomised, Multicentre Study to Compare the Safety and Efficacy of Lamivudine Versus Hepatitis B Immunoglobulin in the Prevention of Hepatitis B Reinfection After Liver Transplantation
NUCB2014 Completed Multicentre, Open Label Compassionate Use Programme for Patients Treated with 100 mg Lamivudine Once Daily for up to 5 Years
NUCB2015 Completed A Study of the Immunobiology of Patients with Chronic Hepatitis B Infection Treated with Lamivudine.Extensive searching has revealed that no clinical study report is available for this study. The Clinical trial results were reported via publication; see citation below.
NUCB2018 Completed The Pharmacokinetics of Epivir (Lamivudine) When Co-Administered With Retrovir (Zidovudine) to HIV-1 Infected Pregnant Women and Their Offspring

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.